These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18950880)

  • 41. Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer.
    Gardner BG; Zietman AL; Shipley WU; Skowronski UE; McManus P
    J Urol; 2002 Jan; 167(1):123-6. PubMed ID: 11743288
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
    Beckendorf V; Guérif S; Le Prisé E; Cosset JM; Lefloch O; Chauvet B; Salem N; Chapet O; Bourdin S; Bachaud JM; Maingon P; Lagrange JL; Malissard L; Simon JM; Pommier P; Hay MH; Dubray B; Luporsi E; Bey P
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1056-65. PubMed ID: 15519775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
    Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects.
    Goldner G; Zimmermann F; Feldmann H; Glocker S; Wachter-Gerstner N; Geinitz H; Becker G; Pötzi R; Wambersie A; Bamberg M; Molls M; Wachter S; Pötter R
    Radiother Oncol; 2006 Jan; 78(1):36-40. PubMed ID: 16271410
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Phase II study of high-dose-rate afterloading brachytherapy as monotherapy for the treatment of localized prostate cancer.
    Corner C; Rojas AM; Bryant L; Ostler P; Hoskin P
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):441-6. PubMed ID: 18249501
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Definitive conformal radiotherapy for localized prostate cancer: a long-term follow-up study.
    Deichmueller CM; Wegener G; Karstens JH; Bruns F
    Anticancer Res; 2009 Jul; 29(7):2627-34. PubMed ID: 19596938
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study.
    Maluta S; Dall'Oglio S; Romano M; Marciai N; Pioli F; Giri MG; Benecchi PL; Comunale L; Porcaro AB
    Int J Hyperthermia; 2007 Aug; 23(5):451-6. PubMed ID: 17701536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer.
    Zelefsky MJ; Kattan MW; Fearn P; Fearon BL; Stasi JP; Shippy AM; Scardino PT
    Urology; 2007 Aug; 70(2):283-7. PubMed ID: 17826490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.
    Peeters ST; Lebesque JV; Heemsbergen WD; van Putten WL; Slot A; Dielwart MF; Koper PC
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1151-61. PubMed ID: 16414208
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of postradiotherapy PSA patterns and correlation with 10-year disease free survival outcomes for prostate cancer.
    Zelefsky MJ; Ben-Porat L; Chan HM; Fearn PA; Venkatraman ES
    Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):382-8. PubMed ID: 16965990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
    Valdagni R; Italia C; Montanaro P; Lanceni A; Lattuada P; Magnani T; Fiorino C; Nahum A
    Radiother Oncol; 2005 Apr; 75(1):74-82. PubMed ID: 15878104
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
    Madsen BL; Hsi RA; Pham HT; Fowler JF; Esagui L; Corman J
    Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1099-105. PubMed ID: 17336216
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bladder and rectal toxicity of BeamCath application in radiotherapy of prostate cancer.
    Hanssen S; Norum J
    Anticancer Res; 2008; 28(5B):2865-8. PubMed ID: 19031926
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II feasibility study of high-dose radiotherapy for prostate cancer using proton boost therapy: first clinical trial of proton beam therapy for prostate cancer in Japan.
    Nihei K; Ogino T; Ishikura S; Kawashima M; Nishimura H; Arahira S; Onozawa M
    Jpn J Clin Oncol; 2005 Dec; 35(12):745-52. PubMed ID: 16314345
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V; De Gersem W; De Neve W; Jacobs F; Lumen N; Vandecasteele K; Villeirs G; De Meerleer G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1013-20. PubMed ID: 19386427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Conformal radiotherapy for patients with clinical stage T1-T3 prostate cancer].
    Majewski W; Miszczyk L; Zajusz A
    Przegl Lek; 2004; 61(5):503-8. PubMed ID: 15515815
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [A five-year experience in conformational radiotherapy in the treatment of prostate cancer. Evaluation of acute toxicity in 131 patients].
    Nasr E; Merhej S; Nehme Nasr D; Fares G; Moukarzel M; Chalouhi E; Bulbul M; Sarkis P; Nemr E; Jabbour M; Khoury R; Ghazale G; Chehade G; Ghosn M; Chahine G; Abillamah A
    Prog Urol; 2005 Feb; 15(1):36-9. PubMed ID: 15822389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical outcome in patients with prostate cancer treated with external beam radiotherapy and high dose-rate iridium 192 brachytherapy boost: a 6-year follow-up.
    Kälkner KM; Wahlgren T; Ryberg M; Cohn-Cedermark G; Castellanos E; Zimmerman R; Nilsson J; Lundell M; Fowler J; Levitt S; Hellström M; Nilsson S
    Acta Oncol; 2007; 46(7):909-17. PubMed ID: 17917823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical correlations between treatment with anticoagulants/antiaggregants and late rectal toxicity after radiotherapy for prostate cancer.
    Takeda K; Ogawa Y; Ariga H; Koto M; Sakayauchi T; Fujimoto K; Narazaki K; Mitsuya M; Takai Y; Yamada S
    Anticancer Res; 2009 May; 29(5):1831-4. PubMed ID: 19443412
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
    Higgins GS; McLaren DB; Kerr GR; Elliott T; Howard GC
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):982-9. PubMed ID: 16750310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.